MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress-Reference-Cited by-同舟云学术

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

Published:2014-05-29 Issue:1 Volume:13 Page:
ISSN:1476-4598
Container-title:Molecular Cancer
language:en
Short-container-title:Mol Cancer

Author:

Felder Mildred,Kapur Arvinder,Gonzalez-Bosquet Jesus,Horibata Sachi,Heintz Joseph,Albrecht Ralph,Fass Lucas,Kaur Justanjyot,Hu Kevin,Shojaei Hadi,Whelan Rebecca J,Patankar Manish S

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine

Link

https://link.springer.com/content/pdf/10.1186/1476-4598-13-129.pdf

Reference177 articles.

1. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M: CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int J Gynecol Cancer. 2005, 15: 679-691. 10.1111/j.1525-1438.2005.00130.x.

2. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih Ie M, Sibley P, Soletormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008, 54: e11-e79. 10.1373/clinchem.2008.105601.

3. Seltzer V, Drukker BH, Gillespie BW, Gossfeld LM, Grigsby PW, Harvey HA, Hendricks CB, Hummel S, Makuch RW, Monaco GP, Parham GP, Sawyers CL, West RJ, Alberts DS, Anderson B, Averette HE, Bast RC, Christian MC, Colombo N, Creasman WT, John P, Curtin JP, Gershenson DM, Hoskins WJ, Karlan BY, Kramer BS, Markman M, McGuire WP, Ozols RF, Pecorelli S: NIH consensus conference: ovarian cancer: screening, treatment, and follow-up. NIH consensus development panel on ovarian cancer. JAMA. 1995, 273: 491-497. 10.1001/jama.1995.03520300065039.

4. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J: Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004, 96: 487-488.

5. Vasudev NS, Trigonis I, Cairns DA, Hall GD, Jackson DP, Broadhead T, Buxton J, Hutson R, Nugent D, Perren TJ: The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Arch Gynecol Obstet. 2011, 284: 221-227. 10.1007/s00404-010-1655-2.

Cited by 386 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated biosensor array for multiplex biomarkers cancer diagnosis via in-situ self-assembly carbon nanotubes with an ordered inverse-opal structure;Biosensors and Bioelectronics;2024-10

2. Natural killer (NK) cells-related gene signature reveals the immune environment heterogeneity in hepatocellular carcinoma based on single cell analysis;Discover Oncology;2024-09-04

3. Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy;Journal of Ovarian Research;2024-08-08

4. Pseudo-Meigs syndrome caused by a rapidly enlarging hydropic leiomyoma with elevated CA125 levels mimicking ovarian malignancy: a case report and literature review;BMC Women's Health;2024-08-07

5. A nomogram predicting distant metastasis risk for gastric cancer patients with preoperative anemia: a multicenter retrospective study;World Journal of Surgical Oncology;2024-08-01